Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Douglas, Teresa D ^a,b   Ramakrishnan, Usha ^c   Kable, Julie A ^a,d   Singh, Rani H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d MARCUS AUTISM CENTER   (United States)

Author keywords

BH4; Medical diet; Phenylketonuria; PKU; Quality of life; Sapropterin; Tetrahydrobiopterin

Indexed keywords

BH 4; PHENYLALANINE; SAPROPTERIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DIETARY INTAKE; DIETITIAN; FEMALE; FOLLOW UP; HUMAN; LIKERT SCALE; MALE; PATIENT MONITORING; PATIENT SATISFACTION; PATIENT WORRY; PHENYLKETONURIA; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SELF REPORT; SOCIAL SUPPORT; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING; YOUNG ADULT;

ADOLESCENT; ADULT; BIOPTERIN; CHILD; FEMALE; GEORGIA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENYLKETONURIAS; QUALITY OF LIFE; SELF REPORT; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84891365572     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-218     Document Type: Article

References (28)

1. Bilginsoy C, et al. Living with phenylketonuria: Perspectives of patients and their families. J Inherit Metab Dis 2005, 28:639-649.
2. Legge FF. Phenylketonuria-the lived experience. J New Zealand Med Assoc 2007, 120:U2728.
3. Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE. Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Hum Nutr Diet 2008, 21:474-485.
4. Aoki K, Ohwada M, Kitagawa T. Long-term follow-up study of patients with phenylketonuria detected by the newborn screening programme in Japan. J Inherit Metab Dis 2007, 30:608-608.
5. Burton BK, et al. A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab 2013, 108:8-12.
6. Arnold GL, et al. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 2004, 27:137-143.
7. Weglage J, et al. Deficits in selective and sustained attention processes in early treated children with phenylketonuria-result of impaired frontal lobe functions?. Eur J Pediatr 1996, 155:200-204.
8. Sharman R, Sullivan K, Young R, McGill J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin Genet 2009, 75:169-174.
9. Azadi B, et al. Executive dysfunction in treated phenylketonuric patients. Eur Child Adolesc Psychiatry 2009, 18:360-368.
10. Christ SE, et al. Inhibitory control in children with phenylketonuria. Dev Neuropsychol 2006, 30:845-864.
11. Stemerdink BA, et al. Behaviour and school achievement in patients with early and continuously treated phenylketonuria. J Inherit Metab Dis 2000, 23:548-562.
12. Simon E, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 2008, 6:25.
13. Bik-Multanowski M, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis 2008, 31(Suppl 2):S415-S418.
14. Gassio R, et al. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?. Acta Paediatr 2003, 92:1474-1478.
15. Utz JR, et al. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 2012, 105:193-197.
16. Singh RH, Quirk ME. Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria. Mol Genet Metab 2011, 104:485-491.
17. Ingersoll M. A modified quality-of-life measure for youths: psychometric properties. Diabetes Educ 1991, 17:114-118.
18. Singh RH, et al. Impact of a Camp Experience on Phenylalanine Levels, Knowledge, Attitudes, and Health Beliefs Relevant to Nutrition Management of Phenylketonuria in Adolescent Girls. J Am Diet Assoc 2000, 100:797-803.
19. Cohen J, Cohen P, West SG, Aiken LS. Statistical Power Analysis for the Behavioral Sciences 1988, Hillsdale, NJ: Lawrence Earlbaum Associates, 2.
20. RH Heck SLT, Tabata LN, Heck RH SLT, Tabata LN. Multilevel and longitudinal modeling with IBM SPSS. G.A. Marcoulides 2010, 343. New York: Routledge, Quantitative Methodology Series, 1.
21. Cotugno G, et al. Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr 2011, 100:1144-1149.
22. Ziesch B, et al. Tetrahydrobiopterin (BH(4)) in PKU: effect on dietary treatment, metabolic control, and quality of life. J Inherit Metab Dis 2012, 35:983-992.
23. Bosch AM, et al. Remarkable differences: the course of life of young adults with galactosaemia and PKU. J Inherit Metab Dis 2009, 32:706-712.
24. Landolt MA, et al. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr 2002, 140:516-521.
25. Gourin CG. Quality of life is more than the sum of its parts. Otolaryngol Head Neck Surg 2008, 139:273-274.
26. Fryback DG, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007, 45:1162-1170.
27. Hanmer J, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006, 26:391-400.
28. Wagner VM, et al. Age, metabolic control and type of insulin regime influences health-related quality of life in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr 2005, 164:491-496.